This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Multiple sclerosis
  • /
  • Long-term safety and tolerability of glatiramer ac...
Journal

Long-term safety and tolerability of glatiramer acetate 20 mg/ml in the treatment of relapsing forms of multiple sclerosis.

Read time: 1 mins
Published:1st Feb 2017
Author: <p>Ziemssen T, Ashtamker N, Rubinchick S, Knappertz V, Comi G.</p>
Availability: Pay for access, or by subscription
Ref.:Expert Opin Drug Saf. 2017;16(2):247-255.
DOI:10.1080/14740338.2017.1274728

?Introduction: Glatiramer acetate (GA) is a first-line therapy for the treatment of relapsing-remitting multiple sclerosis (RRMS). It has a well-characterized long-term safety profile and established efficacy, with over 2 million patient-years of exposure.

Areas covered: To present long-term safety and tolerability findings for GA 20 mg/mL daily in the management of patients with multiple sclerosis (MS). A database analysis of all patients with MS who have ever been exposed to GA 20 mg/mL daily in clinical trials, including patients with up to 20 years of continuous treatment.Total exposure to GA in the clinical trials analyzed was 10,017 patient-years, and treatment duration ranged from 0 to 23.1 years (median 1.8 years). No unexpected adverse events (AEs) were recorded. The most common AEs were injection-site related (ISR), affecting 49% of patients receiving GA in clinical trials. Development of erythema at the injection site was the most common ISR, affecting 29.2% of study patients. Immediate post-injection reactions (IPIRs) were experienced by 24.0% of study patients; dyspnea was the most common IPIR, affecting 12.1% of patients.

Expert opinion: The results of this analysis are consistent with long-term studies showing GA to be safe and generally well tolerated.

 

Read abstract on library site

Access full article